1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Diabetic Macular Edema - Pipeline Review, H1 2016

Diabetic Macular Edema - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 192 pages

Diabetic Macular Edema - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Diabetic Macular Edema - Pipeline Review, H1 2016’, provides an overview of the Diabetic Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
- The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Diabetic Macular Edema - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Macular Edema Overview 8
Therapeutics Development 9
Pipeline Products for Diabetic Macular Edema - Overview 9
Pipeline Products for Diabetic Macular Edema - Comparative Analysis 10
Diabetic Macular Edema - Therapeutics under Development by Companies 11
Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes 14
Diabetic Macular Edema - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Diabetic Macular Edema - Products under Development by Companies 19
Diabetic Macular Edema - Products under Investigation by Universities/Institutes 22
Diabetic Macular Edema - Companies Involved in Therapeutics Development 23
Aciont Inc. 23
ActiveSite Pharmaceuticals, Inc. 24
Acucela Inc. 25
Aerpio Therapeutics, Inc. 26
Allergan Plc 27
Ampio Pharmaceuticals, Inc. 28
Astellas Pharma Inc. 29
Avalanche Biotechnologies, Inc. 30
Chengdu Kanghong Pharmaceuticals Group Co., Ltd. 31
Chong Kun Dang Pharmaceutical Corp. 32
EyeGate Pharmaceuticals, Inc. 33
EyeGene, Inc. 34
Gene Signal International SA 35
Genmab A/S 36
Icon Bioscience, Inc. 37
Kala Pharmaceuticals, Inc. 38
Kowa Company, Ltd. 39
Mabion SA 40
MacuCLEAR, Inc. 41
NicOx S.A. 42
Oculis ehf 43
Ohr Pharmaceutical Inc. 44
Quark Pharmaceuticals, Inc. 45
Regeneron Pharmaceuticals, Inc. 46
Santen Pharmaceutical Co., Ltd. 47
SciFluor Life Sciences, LLC 48
Senju Pharmaceutical Co., Ltd. 49
Shire Plc 50
Sucampo Pharmaceuticals, Inc. 51
ThromboGenics NV 52
Verseon Corporation 53
Xbrane Biopharma AB 54
Diabetic Macular Edema - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Combination Products 56
Assessment by Target 57
Assessment by Mechanism of Action 59
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
(aflibercept + nesvacumab) - Drug Profile 65
abicipar pegol - Drug Profile 66
ACX-107 - Drug Profile 69
aganirsen - Drug Profile 70
AKB-9778 - Drug Profile 72
ALG-1001 - Drug Profile 74
Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 76
ASP-440 - Drug Profile 77
ASP-8232 - Drug Profile 79
ASPPDC-010 - Drug Profile 80
AVA-101 - Drug Profile 81
conbercept - Drug Profile 83
danazol - Drug Profile 85
dexamethasone acetate - Drug Profile 86
dexamethasone acetate - Drug Profile 88
dexamethasone dipropionate - Drug Profile 90
dexamethasone dipropionate XR - Drug Profile 91
difluprednate - Drug Profile 92
Drug for Diabetic Macular Edema - Drug Profile 94
Drugs to Inhibit Semaphorin 3A for Diabetic Macular Edema - Drug Profile 95
EG-Mirotin - Drug Profile 96
emixustat hydrochloride - Drug Profile 97
fluticasone propionate - Drug Profile 99
JDE-006 - Drug Profile 100
KVD-001 - Drug Profile 101
lanadelumab - Drug Profile 102
loteprednol etabonate - Drug Profile 103
MC-4001 - Drug Profile 105
methotrexate - Drug Profile 106
MTP-131 - Drug Profile 107
NCX-422 - Drug Profile 109
NCX-434 - Drug Profile 110
nesvacumab - Drug Profile 111
NM-108 - Drug Profile 113
OLX-303 - Drug Profile 114
PF-655 - Drug Profile 115
ranibizumab biosimilar - Drug Profile 118
ranibizumab biosimilar - Drug Profile 119
ranibizumab biosimilar - Drug Profile 120
RC-1 Alpha - Drug Profile 121
ripasudil - Drug Profile 122
RTU-1096 - Drug Profile 124
RX-10045 - Drug Profile 125
SF-0166 - Drug Profile 127
Small Molecule for Diabetic Macular Edema - Drug Profile 128
Small Molecule to Inhibit Kallikrein for DME - Drug Profile 129
Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile 130
squalamine lactate - Drug Profile 132
teprotumumab - Drug Profile 135
TG-758 - Drug Profile 138
TG-931 - Drug Profile 139
triamcinolone acetonide - Drug Profile 140
Diabetic Macular Edema - Recent Pipeline Updates 141
Diabetic Macular Edema - Dormant Projects 177
Diabetic Macular Edema - Discontinued Products 179
Diabetic Macular Edema - Product Development Milestones 180
Featured News and Press Releases 180
Appendix 187
Methodology 187
Coverage 187
Secondary Research 187
Primary Research 187
Expert Panel Validation 187
Contact Us 187
Disclaimer 188

List of Tables
Number of Products under Development for Diabetic Macular Edema, H1 2016 13
Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Development by Companies, H1 2016 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2016 18
Comparative Analysis by Late Stage Development, H1 2016 19
Comparative Analysis by Clinical Stage Development, H1 2016 20
Comparative Analysis by Early Stage Development, H1 2016 21
Comparative Analysis by Unknown Stage Development, H1 2016 22
Products under Development by Companies, H1 2016 23
Products under Development by Companies, H1 2016 (Contd..1) 24
Products under Development by Companies, H1 2016 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2016 26
Diabetic Macular Edema - Pipeline by Aciont Inc., H1 2016 27
Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H1 2016 28
Diabetic Macular Edema - Pipeline by Acucela Inc., H1 2016 29
Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H1 2016 30
Diabetic Macular Edema - Pipeline by Allergan Plc, H1 2016 31
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 32
Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H1 2016 33
Diabetic Macular Edema - Pipeline by Avalanche Biotechnologies, Inc., H1 2016 34
Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co., Ltd., H1 2016 35
Diabetic Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 36
Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2016 37
Diabetic Macular Edema - Pipeline by EyeGene, Inc., H1 2016 38
Diabetic Macular Edema - Pipeline by Gene Signal International SA, H1 2016 39
Diabetic Macular Edema - Pipeline by Genmab A/S, H1 2016 40
Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H1 2016 41
Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H1 2016 42
Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H1 2016 43
Diabetic Macular Edema - Pipeline by Mabion SA, H1 2016 44
Diabetic Macular Edema - Pipeline by MacuCLEAR, Inc., H1 2016 45
Diabetic Macular Edema - Pipeline by NicOx S.A., H1 2016 46
Diabetic Macular Edema - Pipeline by Oculis ehf, H1 2016 47
Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc., H1 2016 48
Diabetic Macular Edema - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 49
Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 50
Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 51
Diabetic Macular Edema - Pipeline by SciFluor Life Sciences, LLC, H1 2016 52
Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2016 53
Diabetic Macular Edema - Pipeline by Shire Plc, H1 2016 54
Diabetic Macular Edema - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 55
Diabetic Macular Edema - Pipeline by ThromboGenics NV, H1 2016 56
Diabetic Macular Edema - Pipeline by Verseon Corporation, H1 2016 57
Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2016 58
Assessment by Monotherapy Products, H1 2016 59
Assessment by Combination Products, H1 2016 60
Number of Products by Stage and Target, H1 2016 62
Number of Products by Stage and Mechanism of Action, H1 2016 64
Number of Products by Stage and Route of Administration, H1 2016 66
Number of Products by Stage and Molecule Type, H1 2016 68
Diabetic Macular Edema Therapeutics - Recent Pipeline Updates, H1 2016 145
Diabetic Macular Edema - Dormant Projects, H1 2016 181
Diabetic Macular Edema - Dormant Projects (Contd..1), H1 2016 182
Diabetic Macular Edema - Discontinued Products, H1 2016 183

List of Figures
Number of Products under Development for Diabetic Macular Edema, H1 2016 13
Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Investigation by Universities/Institutes, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 20
Comparative Analysis by Early Stage Products, H1 2016 21
Assessment by Monotherapy Products, H1 2016 59
Number of Products by Top 10 Targets, H1 2016 61
Number of Products by Stage and Top 10 Targets, H1 2016 61
Number of Products by Top 10 Mechanism of Actions, H1 2016 63
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 63
Number of Products by Top 10 Routes of Administration, H1 2016 65
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 65
Number of Products by Top 10 Molecule Types, H1 2016 67
Number of Products by Stage and Top 10 Molecule Types, H1 2016 67

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Acyl CoA Desaturase ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.